Uncategorized

BrainTale Has Presented at the European Academy of Neurology and the World Parkinson Congress the Interest of Its Digital Biomarker Platform for the Early and Differential Diagnosis of Parkinson’s Disease

BrainTale, a medtech deciphering white matter to enable better brain care, spin-off of the Paris Region Greater Hospitals, presented preliminary results during the European Academy of Neurology and the World Parkinson congress demonstrating the interest of its digital biomarker platform for the early and differential diagnosis of Parkinson’s disease.

BrainTale Has Presented at the European Academy of Neurology and the World Parkinson Congress the Interest of Its Digital Biomarker Platform for the Early and Differential Diagnosis of Parkinson’s Disease Read More »

Regen Lab partners with Morocco’s Ministries of Health and Industry, Dassault Systèmes, Baylor College of Medicine (US) and SOTHEMA to accelerate regenerative medicine in Morocco and Africa

Regen Lab announces the signing of a collaboration agreement with the Moroccan Ministries of Health and Industry, the Dassault Systèmes group, Baylor College of Medicine and the Moroccan Therapeutic Society, to create a fully integrated global operational structure dedicated to the deployment of regenerative medicine in Morocco and more widely in Africa.

Regen Lab partners with Morocco’s Ministries of Health and Industry, Dassault Systèmes, Baylor College of Medicine (US) and SOTHEMA to accelerate regenerative medicine in Morocco and Africa Read More »

Cipla Issues Voluntary Nationwide Recall of Six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) due to Container Defect

Cipla Limited, announced that its wholly-owned subsidiary Cipla US is voluntarily recalling six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg manufactured in November 2021 to the consumer level.

Cipla Issues Voluntary Nationwide Recall of Six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) due to Container Defect Read More »

Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001)

Transcenta Holding Limited announces that it has received approvals from China CDE and South Korea MFDS to initiate TranStar 301 global Phase III pivotal trial of Osemitamab in combination with Nivolumab and chemotherapy for the first-line treatment of patients with HER2 negative, CLDN18.2 expressing locally advanced or metastatic gastric or gastroesophageal adenocarcinoma.

Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001) Read More »

Scroll to Top